Actively Recruiting
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population: a Cohort Study
Led by Ningbo No. 1 Hospital · Updated on 2025-06-04
2720
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how biological aging relates to the risk of developing type 2 diabetes mellitus (T2DM), especially in people with and without metabolic dysfunction-associated steatotic liver disease (MASLD). They are measuring biological age using methods like phenotypic age, Klemera-Doubal method, and homeostatic dysregulation to see how aging affects diabetes risk. This observational study evaluates these associations using various statistical models to better understand the link between aging and T2DM incidence over time. Participants are grouped based on whether they have MASLD at the start of the study or not. The study collects data from annual health check-ups, including abdominal ultrasound and metabolic indicators like body mass index, blood pressure, cholesterol levels, and blood sugar measurements. No experimental treatments are given, as this is an observational study monitoring participants over an average of three years. During the study, researchers will track the onset of type 2 diabetes by reviewing health records and metabolic data collected yearly. They will assess the incidence of T2DM and analyze how biological aging measures correspond with disease development. The primary outcome is the incidence of new T2DM cases through the study completion. Participants will be observed for about three years, with no interventions applied, allowing researchers to monitor natural disease progression and aging effects.
CONDITIONS
Brief Title
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Abdominal ultrasound data available in annual health check-up records
- At least one of the following five metabolic indicators recorded annually: body mass index or waist circumference, blood pressure, serum triglycerides, high-density lipoprotein cholesterol, fasting plasma glucose or glycated hemoglobin
- Adults aged between 20 and 90 years
- Participants without type 2 diabetes mellitus at baseline
You will not qualify if you...
- Age less than 20 or greater than 90 years
- Other causes of hepatic steatosis such as alcoholic liver disease or hepatitis B infection
- Type 2 diabetes mellitus present at baseline
- Missing baseline data for any of the following: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin, total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, red cell distribution width
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 3 years
Participants are observed over time to assess incidence of type 2 diabetes mellitus and track metabolic indicators.
Annual visits for data collection
Trial Site Locations
Total: 1 location
1
the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000
Ningbo, Zhejiang, China, 315000
Actively Recruiting
Research Team
L
Lei Xu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here